Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.
2.

Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone.

Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Hwang C, Sostek M.

Aliment Pharmacol Ther. 2010 Aug;32(3):401-13. doi: 10.1111/j.1365-2036.2010.04378.x. Epub 2010 May 22. Erratum in: Aliment Pharmacol Ther. 2016 Sep;44(5):539.

3.

Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers.

Miner P Jr, Plachetka J, Orlemans E, Fort JG, Sostek M.

Aliment Pharmacol Ther. 2010 Aug;32(3):414-24. doi: 10.1111/j.1365-2036.2010.04361.x. Epub 2010 May 18. Erratum in: Aliment Pharmacol Ther. 2012 Jan;35(1):207.

4.

Naproxen/esomeprazole fixed-dose combination: for the treatment of arthritic symptoms and to reduce the risk of gastric ulcers.

Dhillon S.

Drugs Aging. 2011 Mar 1;28(3):237-48. doi: 10.2165/11207150-000000000-00000. Review.

PMID:
21329403
5.

Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.

Sostek MB, Fort JG, Estborn L, Vikman K.

Curr Med Res Opin. 2011 Apr;27(4):847-54. doi: 10.1185/03007995.2011.555756. Epub 2011 Feb 14.

PMID:
21319944
6.

Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.

Wang-Smith L, Fort J, Zhang Y, Sostek M.

J Clin Pharmacol. 2012 May;52(5):670-80. doi: 10.1177/0091270011405500. Epub 2011 May 31.

PMID:
21628602
8.
9.

Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials.

Hochberg MC, Fort JG, Svensson O, Hwang C, Sostek M.

Curr Med Res Opin. 2011 Jun;27(6):1243-53. doi: 10.1185/03007995.2011.580340. Epub 2011 Apr 28.

PMID:
21524238
10.

Gastroscopic findings after treatment with enteric-coated and plain naproxen tablets in healthy subjects.

Trondstad RI, Aadland E, Holler T, Olaussen B.

Scand J Gastroenterol. 1985 Mar;20(2):239-42.

PMID:
3887555
11.
12.

Enteric protection of naproxen in a fixed-dose combination product produced by hot-melt co-extrusion.

Vynckier AK, De Beer M, Monteyne T, Voorspoels J, De Beer T, Remon JP, Vervaet C.

Int J Pharm. 2015 Aug 1;491(1-2):243-9. doi: 10.1016/j.ijpharm.2015.06.010. Epub 2015 Jun 9.

PMID:
26068198
13.

Enteric coated naproxen tablets.

Gamst ON.

Eur J Rheumatol Inflamm. 1992;12(2):5-8. Review.

PMID:
1364940
14.

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects.

Hassan-Alin M, Naesdal J, Nilsson-Pieschl C, Långström G, Andersson T.

Clin Drug Investig. 2005;25(11):731-40.

PMID:
17532719
16.

Enteric coated naproxen; a double blind trial comparing the tolerance of enteric coated and standard formulations.

Huskisson EC, Bernstein RM, Coppock JS, Davies PG, Doyle DV, Platt PR, Scott DL, Witherington RH, Wojtulewski JA.

Eur J Rheumatol Inflamm. 1992;12(2):27-30.

PMID:
1364935
18.

Efficacy and tolerability of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis: a double-blind comparison with standard naproxen followed by an open-label trial.

Bellamy N, Beaulieu A, Bombardier C, Huang S, Kraag G, Ménard HA, Russell AS, Tannenbaum H, Willans M, Campbell J.

Curr Med Res Opin. 1992;12(10):640-51.

PMID:
1633722
19.

Endoscopic findings in the stomach and duodenum after treatment with enteric-coated and plain naproxen tablets in healthy subjects.

Oddsson E, Gudjonsson H, Thjodleifsson B.

Scand J Gastroenterol. 1990 Mar;25(3):231-4.

PMID:
2181621
20.

Comparison of the gastrointestinal side effects of naproxen formulated as plain tablets, enteric-coated tablets, or enteric-coated granules in capsules.

Aabakken L, Bjørnbeth BA, Hofstad B, Olaussen B, Larsen S, Osnes M.

Scand J Gastroenterol Suppl. 1989;163:65-73.

PMID:
2814364

Supplemental Content

Support Center